Deals In Depth: October 2013
Executive Summary
Eli Lilly agreed to co-promote Pfizer’s anti-NGF tanezumab for $200 million up front plus $350 million in regulatory milestones; private equity firms Avista and Nordic are taking Swiss pharmaco Acino private in a $439 million deal. Both biopharma and device financing increased in October vs. the previous month thanks to strong showings from IPOs and secondary offerings.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.